Alendrate

Country: New Zealand

Lingwa: Ingliż

Sors: Medsafe (Medicines Safety Authority)

Ingredjent attiv:

Alendronate sodium trihydrate 13.05mg Equivalent to 10 mg alendronic acid;  

Disponibbli minn:

Viatris Limited

INN (Isem Internazzjonali):

Alendronate sodium trihydrate 13.05 mg (Equivalent to 10 mg alendronic acid)

Dożaġġ:

10 mg

Għamla farmaċewtika:

Tablet

Kompożizzjoni:

Active: Alendronate sodium trihydrate 13.05mg Equivalent to 10 mg alendronic acid   Excipient: Croscarmellose sodium Lactose monohydrate Magnesium stearate Microcrystalline cellulose Povidone

Unitajiet fil-pakkett:

Blister pack, PVC/aluminium, 30 tablets

Klassi:

Prescription

Tip ta 'preskrizzjoni:

Prescription

Manifatturat minn:

Pharmaceutical Works Polpharma SA

Indikazzjonijiet terapewtiċi:

Alendrate is indicated: · In postmenopausal women for the treatment of osteoporosis to prevent fractures, including those of the hip and spine (vertebral compression fractures). · In postmenopausal women who are at risk of developing osteoporosis Alendrate is indicated for the prevention of osteoporosis to reduce the risk of future fracture. · For the treatment of osteoporosis in men to prevent fractures. · For the treatment and prevention of glucocorticoid-induced osteoporosis in men, premenopausal women and postmenopausal women receiving oestrogen. · For treatment of Paget's disease of bone in men and women.

Sommarju tal-prodott:

Package - Contents - Shelf Life: Blister pack, PVC/aluminium - 30 tablets - 36 months from date of manufacture stored at or below 25°C

Data ta 'l-awtorizzazzjoni:

2004-04-19